Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 01/27/2014 -- Reportstack, provider of premium market research reports announces the addition of Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013 market report to its offering
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013


, 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis). Retinitis Pigmentosa (Retinitis) - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Retinitis Pigmentosa (Retinitis).
- A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

QLT Inc.
Sangamo BioSciences, Inc.
Sun Pharmaceutical Industries Limited
BioDiem Ltd
ReGenX Biosciences, LLC
ReNeuron Group plc
R-Tech Ueno, Ltd.
Neurotech Pharmaceuticals, Inc.
Orphagen Pharmaceuticals, Inc.
Grupo Ferrer Internacional, S.A.
Stemedica Cell Technologies, Inc.
Asklepios BioPharmaceutical, Inc.
to-BBB technologies BV
Dompe Farmaceutici S.p.A.
DNAVEC Corporation
Bikam Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals Inc.
Genable Technologies Limited
Amarantus Bioscience Holdings, Inc.
ProRetina Therapeutics, S.L
RetroSense Therapeutics, LLC
GenSight Biologics

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604